Regeneron

Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
ASCO: Regeneron's Opdualag rival records double the historical response rate in melanoma
Fierce Biotech
ASCO 2023
Regeneron
advanced melanoma
fianlimab
Flag link:
Sanofi, Regeneron flesh out COPD data with Dupixent
Sanofi, Regeneron flesh out COPD data with Dupixent
Pharmaphorum
Sanofi
Regeneron
COPD
Dupixent
Flag link:
Supreme Court rules against Amgen bid to revive cholesterol drug patents
Supreme Court rules against Amgen bid to revive cholesterol drug patents
KFGO/Reuters
Supreme Court
Amgen
Sanofi
Regeneron
patents
Repatha
legal
Flag link:
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Medical Marketing and Media
Amgen
Horizon Therapeutics
FTC
Regeneron
antitrust
M&A
Leonard Schleifer
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Revenues down for Moderna, up for Regeneron in Q1
Revenues down for Moderna, up for Regeneron in Q1
Medical Marketing and Media
Moderna Therapeutics
Regeneron
earnings
Flag link:
Chronic hives: Four major clinical trials to watch in 2023
Chronic hives: Four major clinical trials to watch in 2023
Clinical Trials Arena
chronic hives
chronic urticaria
clinical trials
Sanofi
Regeneron
dupilumab
Amgen
tezepelumab
Allakos
lirentelimab
Celldex Therapeutics
barzolvolimab
Flag link:
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
Alnylam’s early Alzheimer’s results encourage, but company discloses new hurdle
BioPharma Dive
Alnylam
Regeneron
clinical trials
Alzheimer's disease
ALN-APP
Flag link:
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Activist shareholders ask 9 big pharmas to consider whether 'excessive' patenting hurts access
Fierce Pharma
AbbVie
Amgen
Bristol Myers Squibb
Eli Lilly
Gilead Sceinces
JNJ
Merck
Pfizer
Regeneron
patents
activists
Flag link:
Roche’s new eye drug pressures Eylea with strong launch
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Roche
Vabysmo
Eylea
earnings
Regeneron
Flag link:
After massive equity awards, Regeneron's top 2 execs collected smaller pay packages in 2022
After massive equity awards, Regeneron's top 2 execs collected smaller pay packages in 2022
Fierce Pharma
Regeneron
exective pay
George Yancopoulos
Len Schleifer
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma
REGN5459 Delivers Dose-Dependent Responses in Relapsed/Refractory Myeloma
Onc Live
Regeneron
AACR
REGN5459
relapsed or refractory multiple myeloma
Flag link:
The end of an era: Regeneron chairman Roy Vagelos to retire after 29-year run
The end of an era: Regeneron chairman Roy Vagelos to retire after 29-year run
Fierce Pharma
Regeneron
Roy Vagelos
Len Schleifer
George Yancopoulos
Flag link:
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Regeneron expects $56M IPR&D charge tied to cell therapy pact
Fierce Biotech
Regeneron
earnings
R&D
Sonoma Biotherapeutics
Flag link:
Biopharma stocks go back to bleak
Biopharma stocks go back to bleak
EP Vantage
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Flag link:
5 FDA decisions to watch in the second quarter
5 FDA decisions to watch in the second quarter
BioPharma Dive
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biogen
tofersen
ALS
Seres Therapeutics
C. difficile
Pfizer
GSK
vaccines
RSV
Regeneron
Eylea
Flag link:
Regeneron bets on ‘Treg’ cell therapy with Sonoma deal
Regeneron bets on ‘Treg’ cell therapy with Sonoma deal
BioPharma Dive
Regeneron
Sonoma Biotherapeutics
autoimmune disease
cell therapy
Treg cell therapy
Flag link:
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst
Fierce Pharma
Sanofi
Regeneron
Dupixent
COPD
Flag link:

Pages